Tanespimycin
Tanespimycin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against heat shock protein HSP 90-alpha. In addition, it is known to target hepatocyte growth factor receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 8 | 1 | 1 | — | — | 10 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | 2 | — | — | 4 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 1 | 2 | — | — | 4 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 20 | 2 | — | — | — | 21 |
| Leukemia | D007938 | — | C95 | 12 | 1 | — | — | — | 13 |
| Lymphoma | D008223 | — | C85.9 | 6 | 3 | — | — | — | 9 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 5 | 1 | — | — | — | 6 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 5 | 1 | — | — | — | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 4 | — | — | — | 6 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 4 | 1 | — | — | — | 5 |
| Hodgkin disease | D006689 | — | C81 | 3 | 2 | — | — | — | 5 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 4 | — | — | — | 5 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 2 | — | — | — | 4 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 8 | — | — | — | — | 8 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 8 | — | — | — | — | 8 |
| Myeloid leukemia | D007951 | — | C92 | 6 | — | — | — | — | 6 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 5 | — | — | — | — | 5 |
| Follicular lymphoma | D008224 | — | C82 | 5 | — | — | — | — | 5 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 5 | — | — | — | — | 5 |
| B-cell lymphoma | D016393 | — | — | 5 | — | — | — | — | 5 |
| Mycoses | D009181 | — | B35-B49 | 4 | — | — | — | — | 4 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 4 | — | — | — | — | 4 |
| Sezary syndrome | D012751 | — | C84.1 | 4 | — | — | — | — | 4 |
Show 55 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tanespimycin |
| INN | tanespimycin |
| Description | Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin, 17-AAG) is a derivative of the antibiotic geldanamycin that is being studied in the treatment of cancer, specifically in younger patients with certain types of leukemia or solid tumors, especially kidney tumors.
|
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O |
Identifiers
| PDB | — |
| CAS-ID | 75747-14-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL109480 |
| ChEBI ID | 64153 |
| PubChem CID | 6440175 |
| DrugBank | — |
| UNII ID | 4GY0AVT3L4 (ChemIDplus, GSRS) |
Target
Agency Approved
HSP90AA1
HSP90AA1
Organism
Homo sapiens
Gene name
HSP90AA1
Gene synonyms
HSP90A, HSPC1, HSPCA
NCBI Gene ID
Protein name
heat shock protein HSP 90-alpha
Protein synonyms
epididymis luminal secretory protein 52, epididymis secretory sperm binding protein Li 65p, Heat shock 86 kDa, heat shock 90kD protein 1, alpha, heat shock 90kD protein 1, alpha-like 4, heat shock 90kD protein, alpha-like 4, heat shock 90kDa protein 1, alpha, heat shock protein 90kDa alpha (cytosolic), class A member 1, heat shock protein 90kDa alpha family class A member 1, HSP 86, HSP86, LAP-2, Lipopolysaccharide-associated protein 2, LPS-associated protein 2, Renal carcinoma antigen NY-REN-38
Uniprot ID
Mouse ortholog
Hsp90aa1 (15519)
heat shock protein HSP 90-alpha (P07901)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,570 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
53 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use